VYNE Stockholders Greenlight All Proposals for Yarrow Bioscience Reverse Merger
VYNE has more than doubled off its 52-week low of $0.281 on elevated volume (1.8× avg).
Summary
VYNE Therapeutics stockholders overwhelmingly approved all proposals needed to complete the reverse merger with Yarrow Bioscience, including the share issuance, reverse stock split, and authorized share increase. The vote clears the last major condition for closing the deal, which will bring a new clinical pipeline and $100 million in financing.
Key Events · M&A and Partnerships · VYNE
-
All Merger Proposals Approved
At the July 16 special meeting, stockholders approved all nine proposals, including the share issuance to Yarrow stockholders (Proposal 1: 15.9M for, 137K against), the reverse stock split (Proposal 2: 25.4M for, 551K against), and the authorized share increase to 300M (Proposal 3: 23.9M for, 2.0M against).
-
Reverse Split Ratio Set
The approved reverse stock split will be at a ratio between 1-for-10 and 1-for-70, to be determined by the board and Yarrow, aimed at meeting Nasdaq listing requirements post-merger.
-
Authorized Shares Doubled
Stockholders approved increasing authorized common shares from 150 million to 300 million, providing sufficient headroom for the merger share issuance and future equity needs.
-
Yarrow Equity Plans Approved
The Yarrow Bioscience 2026 Stock Incentive Plan and Employee Stock Purchase Plan were approved (Proposals 4 and 5), enabling the combined company to incentivize employees post-closing.
Analysis · VYNE · Life Sciences
Clearing the final stockholder hurdle, VYNE Therapeutics secured overwhelming approval for all nine proposals tied to its reverse merger with Yarrow Bioscience at the July 16 special meeting. The vote authorizes the issuance of shares representing more than 20% of VYNE's pre-merger outstanding stock, a reverse split at a ratio between 1-for-10 and 1-for-70, and an increase in authorized shares from 150 million to 300 million — each a critical step to consummate the deal. Once closed, the merger will transform VYNE into a clinical-stage biotech focused on YB-101 for Graves' disease, with the combined company set to receive $100 million in pre-closing financing. The overwhelming support (over 99% of votes cast in favor of the share issuance and reverse split) removes uncertainty and signals strong stockholder alignment behind the transaction.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYNE was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.7M. The 52-week trading range was $0.28 to $1.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.